A Bacterium From a Crohn’s Patient’s Gut Kept Mice in Remission Longer

If you have Crohn's disease, you already know the shape of the problem. A drug brings the inflammation down, you feel like yourself again, and then weeks or months later it comes back. Steroids are good at starting a remission and bad at holding one, which is why NIH guidance says corticosteroids should only be used short term. A team in Cleveland went looking for something that might hold the line instead, and the candidate they landed on came from an unlikely place: the stool of a person who already had Crohn's disease.

Key Takeaways

• A Lactobacillus plantarum strain isolated from one Crohn's patient's stool prevented, treated, and delayed relapse of Crohn's-like disease in mice.
• The clearest effect was on relapse. After steroid-induced remission, treated mice gained weight while controls lost it, and their gut inflammation marker stayed low for six more weeks.
• Gut barrier leakiness improved in all three experiments, but microscopic tissue scores did not change in two of them.
• This is mouse work with six animals per group. No probiotic you can buy contains this strain, and human evidence for probiotics in Crohn's is still weak.

Lactobacillus plantarum From a Crohn's Patient's Gut Eased Ileitis in Mice

Researchers at Case Western Reserve University isolated a strain of Lactobacillus plantarum (a lactic-acid-producing gut bacterium) from a stool sample belonging to a person with Crohn's disease, then showed that a daily dose of it reduced intestinal inflammation in mice across three separate experiments. The work, published in Probiotics and Antimicrobial Proteins, grew the strain on acidified culture plates and confirmed its identity by partial 16S rRNA gene sequencing, the standard way of naming a bacterium from its genetic fingerprint. Mice then received 1 x 10⁶ colony-forming units by daily oral gavage, or an equivalent volume of plain saline.

The most striking result came from the arm built to mimic relapse. Mice with established disease were pushed into remission with a week of dexamethasone (a corticosteroid), then given either the bacterium or saline for six weeks. By sacrifice, treated mice were at 111.1% of their starting body weight while controls had dropped to 96.1% (p = 0.004), and blinded tissue-damage scores in the small intestine came in at 6.0 versus 9.6 (p = 0.03).

Why Crohn's Relapse, Not the First Flare, Is the Hard Problem

For most people with Crohn's disease, the recurring failure is maintenance, not rescue. Steroids and immunosuppressants can shut down an active flare, but they carry real costs over time and are not built for long-term use, which leaves a gap that nothing fills cleanly. That gap is why probiotics keep coming up in patient forums, and why the honest answer has stayed disappointing: a Cochrane review of probiotics for induction of remission in Crohn's disease found only one qualifying trial, of eleven patients, and concluded there was insufficient evidence to say anything at all.

That context is what makes this paper worth reading rather than dismissing. The team had already reported, in patients with Crohn's, an inverse relationship between how much Lactobacillus was present in stool and how much fecal myeloperoxidase (an enzyme released by inflammatory immune cells, used here as a marker of gut inflammation) showed up alongside it. Rather than reach for an off-the-shelf commercial strain, they went back to a patient's own gut to find one that had already proven it could survive there.

Three Mouse Experiments Covered Prevention, Active Colitis, and Relapse

The strain was tested in three complementary designs in SAMP1/YitFc mice, a line that spontaneously develops Crohn's-like inflammation of the ileum with 100% penetrance on a predictable schedule. Each experiment used six mice per group, matched for age and sex, with fecal homogenization beforehand to reduce cage-to-cage microbiome differences.

In the acute arm, 14-week-old mice got four weeks of the bacterium before chemically induced colitis. Treated mice held their weight at 99.8% of baseline against 87.8% in controls (p = 0.006) and had colons measuring 7.5 cm versus 5.3 cm (p < 0.01), a shortened colon being a standard readout of colitis severity. Endoscopy scores improved too, at 3.1 versus 5.3 (p = 0.02).

In the prevention arm, four-week-old mice were dosed for eight weeks, before ileitis would normally appear. Body weight tracked identically between groups, but gut permeability, measured by how much of a fluorescent sugar probe leaked from the intestine into the blood, was lower in treated mice (p = 0.03), and the share of visibly abnormal intestinal tissue on three-dimensional imaging fell to 0.6% from 1.9% (p = 0.03).

What a Patient-Derived Strain Does and Does Not Mean for Your Supplement Shelf

Nothing here tells you to buy a Lactobacillus plantarum supplement, and it would be a mistake to read it that way. The strain in this study is a clinical isolate that the authors explicitly note has not been compared, genetically or functionally, to any previously described anti-inflammatory Lactobacillus. Probiotic effects are strain-specific, a point the NIH's complementary health center makes plainly in its overview of what is and is not known about probiotics: one Lactobacillus helping with something says nothing about another. That same overview notes a review of fourteen studies in Crohn's disease that found no evidence probiotics helped.

The authors go further and argue against their own product category. They write that single-strain probiotics may be less effective in Crohn's because sustained colonization is fought off by the resident microbiota, ongoing inflammation, and altered intestinal transit, and they suggest multi-strain formulations may be the better bet. If you are managing Crohn's disease, the useful move here is not a purchase. It is telling your gastroenterologist what supplements you already take, and treating patient-derived strains as a research direction to follow rather than a shelf product to try.

Six Mice Per Group and Histology Scores That Did Not Budge

The limitations are substantial, and the paper is reasonably candid about most of them. Six animals per group is small even by mouse-study standards, and everything here happened in a genetically predisposed mouse line, not a person. More pointedly, microscopic tissue scores, the closest thing to a gold standard, failed to separate the groups in two of the three experiments: 10.3 versus 9.6 in the colitis arm (p = 0.65) and 16.0 versus 16.4 in the prevention arm (p = 0.7). Only the relapse arm showed a histology difference. The paper's own discussion section describes the colitis arm as producing lower histology scores, which its results section does not support.

The authors' explanation is that permeability and inflammation markers respond earlier in healing than microscopic architecture does, and that whole-organ imaging catches patchy damage a single tissue section misses. That is plausible. It is also the sort of reasoning that needs a larger, independent replication before it counts as an answer rather than an argument.

What Comes Next for This Crohn's-Derived Strain

The paper describes no human trial and sets no timeline, which is the honest state of things. What it establishes is that one strain from one patient produced consistent, internally coherent effects across prevention, active inflammation, and relapse in the same mouse model. That combination is unusual enough to justify the next steps: genomic and functional characterization against known anti-inflammatory strains, replication in larger groups, and eventually testing in people, most likely as part of a multi-strain formulation rather than alone.

For readers tracking Crohn's research, the thing to watch is not this strain by name. It is whether the patient-derived approach, mining a sick gut for the organisms that were surviving in it, starts producing candidates that hold up in human trials. Until then, Crohn's disease management stays where it is.

Common Questions

Can I buy this probiotic? No. This is a clinical isolate cultured in a research lab from a single patient's stool sample, and it is not a commercial product. No probiotic on the market is known to contain this strain.

Does this mean Lactobacillus plantarum supplements help Crohn's disease? No. Probiotic effects are strain-specific, and reviews of probiotics in Crohn's disease have not found consistent benefit. This study tested one specific isolate in mice.

Why does it matter that the bacterium came from a Crohn's patient? The researchers reasoned that a strain already living in an inflamed gut has proven it can tolerate that environment, which is where many commercial strains fail. They suggest this adaptation may help explain its effects.

What is fecal myeloperoxidase? It is an enzyme released by inflammatory immune cells that shows up in stool, and this group uses it as a marker of intestinal inflammation in both mice and humans. In the relapse experiment it stayed low in treated mice, at 4.7 versus 7.3 in controls (p = 0.004).

References

Drishtant Singh, Ankita Achanta, Paola Menghini, et al. (2026). Lactobacillus plantarum Attenuates Intestinal Inflammation and Prolongs Remission in Experimental Models of Crohn’s Disease. Probiotics and Antimicrobial Proteins. https://doi.org/10.1007/s12602-026-11166-9